HoneyNaps Registers as CRO, Accelerating AI-Powered Sleep Data Analytics for Global Clinical Trials
Key Insights
HoneyNaps (search) has officially registered as a Contract Research Organization with Korea's KoNECT, marking its expansion into AI-driven sleep data analytics for clinical trials.
The company's SOMNUM Clinical (search) platform, powered by FDA-cleared AI, automates polysomnography analysis and can reduce analysis time by more than 90%.
Sleep is increasingly recognized as a critical digital biomarker across therapeutic areas including obesity (search), cardiovascular disease (search), neurodegenerative disorders (search), and mental health.
HoneyNaps (search), a Boston-based AI sleep analytics company, announced on July 27, 2026 that it has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise for Clinical Trials (KoNECT). The registration positions the company to accelerate its AI-powered sleep data analytics services for global pharmaceutical, medical device, and digital health companies conducting clinical trials.
The move comes as sleep medicine gains recognition as an important digital biomarker across a broadening spectrum of therapeutic areas, extending well beyond traditional sleep disorders to encompass obesity (search), cardiovascular disease (search), neurodegenerative disorders (search), mental health, and other conditions.
SOMNUM Clinical (search): AI-Powered Analytics Platform
At the core of HoneyNaps (search)' CRO offering is SOMNUM Clinical (search), an AI-powered clinical trial analytics service built on SOMNUM AI, the company's sleep analysis solution that has received two U.S. FDA clearances. The platform automatically analyzes polysomnography (PSG) data and provides quantitative assessment of key sleep parameters, including sleep stages, apnea-hypopnea index (AHI), arousal events, and other clinically relevant sleep metrics.
According to the company, SOMNUM Clinical (search) can reduce analysis time by more than 90%, addressing one of the major operational challenges in sleep-related clinical trials: the traditionally labor-intensive analysis of polysomnography data. The service applies standardized scoring criteria based on the American Academy of Sleep Medicine (AASM) guidelines, enabling objective, reproducible, and consistent sleep analysis across multiple study sites. By minimizing inter-site and inter-scorer variability, the platform delivers high-quality clinical data suitable for multicenter global clinical trials.
Clinical Experience and Market Opportunity
HoneyNaps (search) brings substantial clinical research expertise to its CRO operations, having supported clinical studies involving more than 10,000 participants and managed nationwide multicenter and multidisciplinary clinical trials. This integrated capability enables the company to deliver both advanced AI analytics and comprehensive clinical trial support for global research programs.
The market opportunity is considerable. According to Dataintelo's Clinical Sleep Health Market report, the global clinical sleep health market is projected to grow from approximately USD 22.8 billion in 2025 to USD 36.9 billion by 2034.
"Sleep medicine is rapidly emerging as an important digital biomarker across a wide range of therapeutic areas, increasing the need for objective and standardized analysis in clinical research," said Sean Ha (Tae Kyoung Ha), President of HoneyNaps (search) USA. "With our CRO registration and AI-powered analytics platform, we are expanding beyond sleep disorder studies to support clinical trials involving pharmaceuticals, wearable devices, digital therapeutics (DTx), obesity (search), neurological diseases, and many other healthcare innovations. Our goal is to become a global leader in AI-driven clinical trial analytics powered by digital biomarkers."
The company is headquartered in Cambridge, Massachusetts, and maintains its operational base at One Broadway.